4-Hydroxyisoleucine

Research use only, not for human use.

4-Hydroxyisoleucine has antidepressant-like antidyslipidemic and antihyperglycemic effects. It displays an insulinotropic activity.

4-Hydroxyisoleucine has antidepressant-like antidyslipidemic and antihyperglycemic effects. It displays an insulinotropic activity.

Cell Viability Assay Cell Line:RAW264.7 macrophages and 3 T3-L1 adipocytes Concentration:0-20 μM Incubation Time:6 h Result:Didn’t affect the cell viability.Cell Migration Assay Cell Line:RAW264.7 macrophages and 3 T3-L1 adipocytes Concentration:20 μM Incubation Time:24 h Result:Inhibited the migration of RAW264.7 macrophages in 3 T3-L1 adipocytes.Western Blot Analysis Cell Line:L6-GLUT4mycConcentration:25 μM Incubation Time:16 h Result:Increased the AKT (Ser-473) phosphorylation.

Animal Model:Fructose-fed rat Dosage:50 mg/kg Administration:Oral gavage (p.o.), daily, 8 weeksResult:Decreased the levels of glucose and ALT.Reduced 80% of fructosehe-induced AST release to 151 ± 45 U/mL.Animal Model:Type 2 diabetic rat Dosage:50 mg/kg Administration:i.g., daily, 14 days Result:Restored the level of HDL-cholesterol to levels comparable to controls.Animal Model:Male C57BL/6 mice Dosage:50-200 mg/kg Administration: Oral gavage (p.o.), 8 weeks Result:Decreases the body weights of mice in a dose-dependent manner.Decreased blood glucose levels and fasting plasma insulin content in mice.Decreased the expression of TLR4, inhibited the phosphorylation of JNK, and increased the production of IκB-α.Animal Model:Type 1 diabetic ratDosage:50 mg/kg Administration: i.g., daily, 14 days Result:Improved appearance and heavy ocular vascularization.Reduced the blood glucose from 500 mg/dl to 330 mg/dl.Decreased the levels of lipid markers (TG, LDL and HDL) and uric acid.

4-?Hydroxy-?L-?isoleucine

Others

Other Targets

Others

——

——

781658-23-9

147.17

C6H13NO3

>98% (HPLC)

In Vitro:?H2O : 100 mg/mL (679.49 mM)

CC(O)[C@H](C)[C@H](N)C(=O)O

——

(-20℃)

With Ice Pack

≥ 2 years